2025-522307-14-00RecruitingPhase 1
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Feb 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 11 Aug 2025
- Start date
- 19 Jan 2026
- Lead sponsor
- Intas Pharmaceuticals Limited
- Diseases
- Melanoma
- EU CT number
- 2025-522307-14-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 34
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (9)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario de Badajoz | Badajoz | Spain | Recruiting |
| Hospital Clinic de Barcelona | Barcelona | Spain | Recruiting |
| Hospital San Pedro De Alcántara | Cáceres | Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Recruiting |
| Hospital Universitario Regional de Málaga | Málaga | Spain | Recruiting |
| Hospital Quironsalud Malaga | Málaga | Spain | Recruiting |
| Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti | Bucharest | Romania | Recruiting |
| Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca | Cluj-Napoca | Romania | Recruiting |
| Centrul De Oncologie SF Nectarie S.R.L. | Craiova | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.